# reload+after+2024-01-23 15:44:04.486010
address1§95 Sawyer Road
address2§Suite 110
city§Waltham
state§MA
zip§02453
country§United States
phone§781 652 4500
website§https://www.checkpointtx.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Checkpoint Therapeutics, Inc., a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's lead antibody product candidate is Cosibelimab, a fully-human monoclonal antibody of IgG1 subtype that directly binds to programmed death ligand-1 (PD-L1) and blocks the PD-L1 interaction with the programmed death receptor-1 and B7.1 receptors; and CK-302, a human agonistic antibody that is designed to bind to and trigger signaling in GITR expressing cells. It is also developing Olafertinib, a third-generation epidermal growth factor receptor (EGFR) inhibitor, as a treatment for patients with EGFR mutation-positive non-small cell lung cancer; CK-103, a selective and potent small molecule inhibitor of bromodomain and extra-terminal bromodomains; and anti-carbonic anhydrase IX (CAIX) antibody, a fully human preclinical antibody to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. The company has collaboration agreements with TG Therapeutics, Inc. to develop and commercialize certain assets in connection with its licenses in the field of hematological malignancies. The company was incorporated in 2014 and is based in Waltham, Massachusetts. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.
fullTimeEmployees§24
companyOfficers§[{'maxAge': 1, 'name': 'Mr. James F. Oliviero III, C.F.A.', 'age': 47, 'title': 'President, CEO & Director', 'yearBorn': 1976, 'fiscalYear': 2022, 'totalPay': 891000, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. William Garrett Gray', 'age': 36, 'title': 'CFO, Corporate Secretary & Treasurer', 'yearBorn': 1987, 'fiscalYear': 2022, 'totalPay': 365750, 'exercisedValue': 0, 'unexercisedValue': 0}]
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§1.387
priceToSalesTrailing12Months§328.81372
currency§USD
dateShortInterest§1702598400
forwardEps§-1.31
exchange§NCM
quoteType§EQUITY
shortName§Checkpoint Therapeutics, Inc.
longName§Checkpoint Therapeutics, Inc.
firstTradeDateEpochUtc§1482157800
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§0b6333fa-c8dd-3277-b59f-9dbaa499e00b
gmtOffSetMilliseconds§-18000000
targetHighPrice§34.0
targetLowPrice§4.0
targetMeanPrice§18.25
targetMedianPrice§17.5
recommendationMean§1.7
recommendationKey§buy
numberOfAnalystOpinions§4
quickRatio§0.085
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
